Radium-223 dichloride treatment for prostate cancer with bone metastases: A symptomatic outcome review of 12 months experience

被引：0
|
作者：
Lee, H. H. [1 ]
McAddy, N. C. [1 ]
O'Sullivan, P. [1 ]
Crawley, P. [1 ]
Beesley, S. [2 ]
Naji, M. [1 ]
机构：
[1] Maidstone & Tunbridge Wells NHS Trust, Nucl Med Dept, Maidstone, Kent, England
[2] Maidstone & TunbridgeWells NHS Trust, Dept Oncol, Maidstone, Kent, England
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPW18
引用
收藏
页码：S214 / S215
页数：2
相关论文
共 50 条
  • [21] Treatment outcome of radium-223 treatment for castration-resistant prostate cancer and bone metastases at a single university hospital
    Takayama, T.
    Sugihara, T.
    Kameda, T.
    Yamazaki, M.
    Komatsubara, M.
    Kamei, J.
    Fujisaki, A.
    Ando, S.
    Fujimura, T.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2022, 20 (01): : 75 - 81
  • [22] Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and bone metastases
    Exadaktylou, P.
    Paschali, A.
    Panagiotidis, E.
    Papadopoulos, N.
    Kalathas, T.
    Giannoula, E.
    Kotzasarlidou, M.
    Chatzipavlidou, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S569 - S570
  • [23] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Uemura, Hiroji
    Uemura, Hirotsugu
    Matsubara, Nobuaki
    Kinuya, Seigo
    Hosono, Makoto
    Yajima, Yoko
    Doi, Toshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 954 - 963
  • [24] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Hiroji Uemura
    Hirotsugu Uemura
    Nobuaki Matsubara
    Seigo Kinuya
    Makoto Hosono
    Yoko Yajima
    Toshihiko Doi
    International Journal of Clinical Oncology, 2017, 22 : 954 - 963
  • [25] Treatment of patients with castration-resistant prostate cancer and bone metastases with radium-223: A single institution experience
    Devarakonda, Srinivas S.
    Skweres, Justin
    Nair, Binu Sivaraman
    Dhawan, Manish
    Takalkar, Amol
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Efficacy and tolerance of radium-223 dichloride in patients treated for castration-resistant prostate cancer with bone metastases
    Awoudou, C.
    Bathily, E. H. A. L.
    Djigo, M. S.
    Ndong, B.
    Mbodj, M.
    Paulus, P.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2024, 48 (03): : 150 - 157
  • [27] Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why
    Gallicchio, Rosj
    Mastrangelo, Pietro A.
    Nardelli, Anna
    Mainenti, Pier Paolo
    Colasurdo, Antonio P.
    Landriscina, Matteo
    Guglielmi, Giuseppe
    Storto, Giovanni
    TUMORI JOURNAL, 2019, 105 (05): : 367 - 377
  • [28] Radium-223 for men with hormone-refractory prostate cancer and bone metastases
    Shelley, Mike D.
    Mason, Malcolm D.
    LANCET ONCOLOGY, 2007, 8 (07): : 564 - 565
  • [29] Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer
    Pratt, Brenda E.
    Hindorf, Cecilia
    Chittenden, Sarah J.
    Parker, Christopher C.
    Flux, Glenn D.
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (02) : 125 - 130
  • [30] Mechanistic Modeling of Radium-223 Treatment of Bone Metastases
    Moreira, Hugo M. R.
    Guerra Liberal, Francisco D. C.
    O'Sullivan, Joe M.
    McMahon, Stephen J.
    Prise, Kevin M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (05): : 1221 - 1230
12345